Get the Stockscreener App
14.88
1.36%
0.20
After Hours:
15.53
0.65
+4.37%
Eton Pharmaceuticals Inc Stock (ETON) Latest News
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - Marketscreener.com
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Canada Finance
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
(ETON) On The My Stocks Page - Stock Traders Daily
Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India
Eton Pharma rises on study results for rare disease drug - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Trading (ETON) With Integrated Risk Controls - Stock Traders Daily
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - GlobeNewswire
How Will Eton's Rare Disease Acquisitions Impact Future Growth? Investor Day Set to Reveal Strategy - StockTitan
Eton Pharmaceuticals Launches Galzin Capsules for Wilson Disease Treatment -March 03, 2025 at 11:48 am EST - Marketscreener.com
Eton Pharmaceuticals launches FDA-approved Wilson disease treatment - Investing.com
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules - GlobeNewswire
Only FDA-Approved Zinc Treatment for Wilson Disease Now AvailableWhat Makes Galzin Different? - StockTitan
60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Anchor Capital Advisors LLC - MarketBeat
(ETON) Trading Report - Stock Traders Daily
Acuitas Investments LLC Has $2.48 Million Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
Insider Buying: Opaleye Management Inc., Eton Pharmaceuticals Inc [ETON] 10% Owner invested 10,000 shares - Knox Daily
What Are You Thinking About Investing In Eton Pharmaceuticals Inc (NASDAQ: ETON) Stock? - Stocks Register
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going - MSN
Learn to Evaluate (ETON) using the Charts - Stock Traders Daily
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 - MSN
FDA extends target action date for Eton's ET-400 - MSN
Eton Pharmaceuticals Receives FDA Extension for NDA for ET-400On February 6, 2025, Eton Pharmaceuticals, Inc. announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUF - Defense World
Eton Pharmaceuticals receives new U.S. patent for ET-600 - MSN
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors - Simply Wall St
Eton Pharmaceuticals Says US Patent Granted for ET-600 Formulation -February 07, 2025 at 07:09 am EST - Marketscreener.com
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 - The Manila Times
Major Patent Win: Eton's Game-Changing Liquid Diabetes Drug Gets 20-Year Protection - StockTitan
Eton Pharmaceuticals Says ET-400 FDA Decision Delayed to May -February 06, 2025 at 10:15 am EST - Marketscreener.com
Eton Pharmaceuticals : FDA Extends ET-400 Review to Late May -February 06, 2025 at 08:37 am EST - Marketscreener.com
Eton Pharmaceuticals: FDA Extends ET-400 Review to Late May - MarketWatch
Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28 - TipRanks
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 - GlobeNewswire
Eton's Pediatric Rare Disease Drug Faces 3-Month FDA Review ExtensionRevenue Outlook Unchanged - StockTitan
Baader Bank Aktiengesellschaft Takes $373,000 Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):